|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...100101102103104105106107108109110...156157» |
- Enrollment change: EPICOM: Study of Offspring of Women With Type 1 Diabetes (clinicaltrials.gov) - Mar 30, 2014
P=N/A, N=584, Active, not recruiting, Sponsor: Odense University Hospital
N=900 --> 584
- Clinical: CL4M-Controls: Improving Postprandial Glycaemia by a New Developed Closed-loop Control System - Closedloop4meals (clinicaltrials.gov) - Mar 30, 2014
P=N/A, N=20, Not yet recruiting, Sponsor: Fundación para la Investigación del Hospital Clínico de Valencia
- ||| vobarilizumab (ALX-0061) / Sanofi
New P1 trial, IO biomarker: ALX-0061 Phase I Bioavailability Study in Healthy Volunteers (clinicaltrials.gov) - Mar 30, 2014
P1, N=70, Recruiting, Sponsor: Ablynx
- Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment closed: A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Mar 30, 2014
P=N/A, N=44, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=900 --> 584 Recruiting --> Active, not recruiting
- Enrollment closed: EPICOM: Study of Offspring of Women With Type 1 Diabetes (clinicaltrials.gov) - Mar 30, 2014
P=N/A, N=584, Active, not recruiting, Sponsor: Odense University Hospital
Recruiting --> Active, not recruiting Enrolling by invitation --> Active, not recruiting
- Enrollment closed: MonoPepT1De: Safety Study to Assess Whether Proinsulin Peptide Injections Can Slow or Stop the Body Damaging Its Own Insulin-making Cells in the Pancreas in Patients Newly Diagnosed With Type 1 Diabetes (clinicaltrials.gov) - Mar 30, 2014
P1/2, N=24, Active, not recruiting, Sponsor: Cardiff University
Enrolling by invitation --> Active, not recruiting Recruiting --> Active, not recruiting
- || Doptelet (avatrombopag) / SOBI
Trial completion: Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02) (clinicaltrials.gov) - Mar 30, 2014
P3, N=49, Completed, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- monalizumab (IPH2201) / AstraZeneca, Innate
Trial completion: Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 30, 2014
P1, N=92, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Lantus (insulin glargine) / Sanofi
Trial completion: Lantus-P-CN: Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old. (clinicaltrials.gov) - Mar 30, 2014
P3, N=162, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Rituxan (rituximab) / Roche
Trial completion: A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor. (clinicaltrials.gov) - Mar 30, 2014
P4, N=60, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda
Trial initiation date: Phase II Study to Evaluate the Efficacy and Safety of Glassia (clinicaltrials.gov) - Mar 29, 2014
P2/3, N=192, Recruiting, Sponsor: Kamada, Ltd.
Active, not recruiting --> Completed Initiation date: Dec 2013 --> Mar 2014
- |||||| Glassia (alpha1-proteinase inhibitor (Human)) / Kamada, Takeda
Enrollment open: Phase II Study to Evaluate the Efficacy and Safety of Glassia (clinicaltrials.gov) - Mar 29, 2014
P2/3, N=192, Recruiting, Sponsor: Kamada, Ltd.
Initiation date: Dec 2013 --> Mar 2014 Not yet recruiting --> Recruiting
- Clinical: Implementing Physical Activity Guidelines for Adults With MS (clinicaltrials.gov) - Mar 27, 2014
P=N/A, N=130, Not yet recruiting, Sponsor: McMaster University
- Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Trial completion, Immunomodulating: Neulasta in Type 1 Diabetes (clinicaltrials.gov) - Mar 27, 2014
P1/2, N=21, Completed, Sponsor: University of Florida
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | solcitinib (GSK2586184) / Galapagos
P2 data, Trial termination: An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184 (clinicaltrials.gov) - Mar 26, 2014
P2, N=51, Terminated, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Recruiting --> Terminated; This study met a protocol defined futility criterion and will be terminated following completion of the Follow Up Visit on the last subject randomised.
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial termination, MRI: A Study of Efficacy of Rituximab [Mabthera/Rituxan] in Patients With Rheumatoid Arthritis Using Magnetic Resonance Imaging of the Hand (RESONAR) (clinicaltrials.gov) - Mar 26, 2014
P4, N=2, Terminated, Sponsor: Hoffmann-La Roche
Recruiting --> Terminated; This study met a protocol defined futility criterion and will be terminated following completion of the Follow Up Visit on the last subject randomised. Completed --> Terminated; This study was prematurely terminated as 2 patients were recruited and both of them withdrawn from the study before reaching the primary end point.
- ||||| Sativex (nabiximols) / Jazz
P3 data, Trial initiation date: Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis. (clinicaltrials.gov) - Mar 26, 2014
P3, N=711, Not yet recruiting, Sponsor: GW Pharmaceuticals Ltd.
Completed --> Terminated; This study was prematurely terminated as 2 patients were recruited and both of them withdrawn from the study before reaching the primary end point. Initiation date: May 2014 --> Sep 2014
- ||||| Sativex (nabiximols) / Jazz
P3 data, Enrollment change: Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis. (clinicaltrials.gov) - Mar 26, 2014
P3, N=711, Not yet recruiting, Sponsor: GW Pharmaceuticals Ltd.
Initiation date: May 2014 --> Sep 2014 N=300 --> 711
- solcitinib (GSK2586184) / Galapagos
P2 data, Enrollment change: An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184 (clinicaltrials.gov) - Mar 26, 2014
P2, N=51, Terminated, Sponsor: GlaxoSmithKline
N=300 --> 711 N=250 --> 51
- | Savella (milnacipran) / AbbVie, Pierre Fabre
Trial completion: Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis (clinicaltrials.gov) - Mar 26, 2014
P4, N=49, Completed, Sponsor: Brigham and Women's Hospital
N=250 --> 51 Active, not recruiting --> Completed
- Clinical: Safety and Efficacy of Overnight Closed Loop in Children With Type 1Diabetes Mellitus in Luxembourg (clinicaltrials.gov) - Mar 26, 2014
P=N/A, N=15, Recruiting, Sponsor: Centre Hospitalier du Luxembourg
- || Victoza (liraglutide) / Novo Nordisk
New P3 trial: ADJUNCT TWO: The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes (clinicaltrials.gov) - Mar 26, 2014
P3, N=804, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||||||||| dimethyl fumarate / Generic mfg.
New P3 trial: Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis. (clinicaltrials.gov) - Mar 25, 2014
P3, N=68, Not yet recruiting, Sponsor: Biogen Idec
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
New P3 trial: A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies (clinicaltrials.gov) - Mar 25, 2014
P3, N=341, Completed, Sponsor: Hoffmann-La Roche
- fletikumab (NNC109-0012) / Novo Nordisk
New P2 trial, Biopsy: A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate (clinicaltrials.gov) - Mar 25, 2014
P2, N=42, Recruiting, Sponsor: Novo Nordisk A/S
- Enrollment open: FMD-ABRA: Full Mouth Disinfection and Antibiotics for Periodontitis in High or Moderate Disease Activity Rheumatoid Arthritis (clinicaltrials.gov) - Mar 25, 2014
P=N/A, N=10, Recruiting, Sponsor: University Hospital Inselspital, Berne
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment open: Impact of CRISP on Self-Efficacy, Loneliness, and Depression (clinicaltrials.gov) - Mar 25, 2014
P=N/A, N=100, Recruiting, Sponsor: New York University School of Medicine
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
New P1 trial: Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Mar 25, 2014
P1, N=100, Recruiting, Sponsor: Regeneron Pharmaceuticals
- ||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Enrollment open: Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Mar 25, 2014
P1, N=100, Recruiting, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| esomeprazole / Generic mfg.
Trial completion: Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation (clinicaltrials.gov) - Mar 25, 2014
P=N/A, N=369, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | New P2 trial: EMR200109_635: Vitamin D3 and the Stress-axis in MS (clinicaltrials.gov) - Mar 24, 2014
P2, N=80, Not yet recruiting, Sponsor: Academic MS Center Limburg
- | Saphnelo (anifrolumab) / AstraZeneca
Enrollment closed: Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus. (clinicaltrials.gov) - Mar 24, 2014
P2, N=19, Active, not recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion: Vitamin D3 in Systemic Lupus Erythematosus (clinicaltrials.gov) - Mar 24, 2014
P2, N=57, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial termination: START: Study of Antithymocyte Globulin for Treatment of New-onset T1DM (clinicaltrials.gov) - Mar 24, 2014
P2, N=58, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Slow accrual
- Enrollment change: Type 1 Diabetes Mellitus Bone Mineral Density in Childhood and Adolescence (clinicaltrials.gov) - Mar 24, 2014
P=N/A, N=60, Completed, Sponsor: Creighton University
Active, not recruiting --> Terminated; Slow accrual N=100 --> 60
- Enrollment open: Assessment of a New Closed-loop Algorithm in Type 1 Diabetes (Saddle Point Model Predictive Control : SP-MPC) (PPA) (clinicaltrials.gov) - Mar 24, 2014
P=N/A, N=10, Recruiting, Sponsor: Rennes University Hospital
N=100 --> 60 Not yet recruiting --> Recruiting
- Enrollment open: Gluten Immunity and Islet Autoimmunity in Type-1 Diabetes (clinicaltrials.gov) - Mar 24, 2014
P=N/A, N=52, Recruiting, Sponsor: Joslin Diabetes Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Trial completion: Type 1 Diabetes Mellitus Bone Mineral Density in Childhood and Adolescence (clinicaltrials.gov) - Mar 24, 2014
P=N/A, N=60, Completed, Sponsor: Creighton University
Not yet recruiting --> Recruiting Recruiting --> Completed
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Trial completion: Proleukin and Rapamune in Type 1 Diabetes (clinicaltrials.gov) - Mar 24, 2014
P1, N=9, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Active, not recruiting --> Completed
- | Rituxan (rituximab) / Roche
Trial completion: PROLONG: Rituximab as Second Line Treatment for ITP (clinicaltrials.gov) - Mar 24, 2014
P3, N=112, Completed, Sponsor: Ostfold Hospital Trust
Active, not recruiting --> Completed Active, not recruiting --> Completed
- fletikumab (NNC109-0012) / Novo Nordisk
Enrollment open, Biopsy: A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate (clinicaltrials.gov) - Mar 23, 2014
P2, N=42, Recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies (clinicaltrials.gov) - Mar 23, 2014
P3, N=341, Completed, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- |||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Enrollment open: SARIL-RA-EASY: To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 23, 2014
P3, N=200, Recruiting, Sponsor: Sanofi
Not yet recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment closed: A Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Mar 23, 2014
P3, N=72, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial completion: A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes (clinicaltrials.gov) - Mar 23, 2014
P1, N=44, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion: Core Stability Training in Multiple Sclerosis (clinicaltrials.gov) - Mar 20, 2014
P=N/A, N=100, Completed, Sponsor: University of Plymouth
Active, not recruiting --> Completed Recruiting --> Completed
- ||||||| tabalumab (LY2127399) / Eli Lilly
Trial completion: An Open Label Study for Participants With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 20, 2014
P3, N=1505, Completed, Sponsor: Eli Lilly and Company
Recruiting --> Completed Active, not recruiting --> Completed
- Trial initiation date: Early Feasibility Study of Adaptive Advisory/Automated (AAA) Control of Type 1 Diabetes (clinicaltrials.gov) - Mar 20, 2014
P=N/A, N=36, Recruiting, Sponsor: Sue Brown
Active, not recruiting --> Completed Initiation date: Sep 2013 --> Dec 2013
- | oral insulin (ORMD-0801) / Oramed
New P2 trial: A Prospective, Randomized, Double-blind, Placebo Controlled Study to Assess the Impact of ORMD-0801 (Insulin Capsules) on the Exogenous Insulin Requirements of Type 1 Diabetics (clinicaltrials.gov) - Mar 20, 2014
P2, N=24, Recruiting, Sponsor: Oramed, Ltd.
- remtolumab (ABT-122) / AbbVie
Enrollment closed: A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 20, 2014
P1, N=24, Active, not recruiting, Sponsor: AbbVie
Initiation date: Sep 2013 --> Dec 2013 Recruiting --> Active, not recruiting